Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Somatogen (SMTG) -- Ignore unavailable to you. Want to Upgrade?

To: Gregory Cole Brock who wrote (420)	2/26/1998 5:21:00 PM
From: RalphLStevens,MD	Read Replies (1) \| Respond to of 442

Any thoughts on the new BAX/SMTG combo, which should be taking shape in the next 2 months? I'd venture that they'll come to dominate the 1st generation market, given Baxter's financial muscle and Somatogen low cost for production of unlimited amounts of recombinant hemoglobin. Longer term, I'd suspect Baxter's money will enable extensive research,synthesis and production of ever larger, longer acting and less vasoactive hemoglobins, for a much expanded array of indications.